Press release
Chlamydia Infections Pipeline, Clinical Trials Assessment, NDA Approvals, Emerging Drugs 2023 (Updated) | Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others
chlamydia infections pipeline
In the Chlamydia Infections Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chlamydia Infections NDA approvals (if any), and product development activities comprising the technology, Chlamydia Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Chlamydia Infections pipeline treatment landscape of the report, click here @ Chlamydia Infections Pipeline- https://www.delveinsight.com/report-store/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Chlamydia Infections Pipeline Report
• DelveInsight's Chlamydia Infections Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading Chlamydia Infections Companies working in the market include Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.
• Promising Chlamydia Infections Pipeline Therapies in the various stages of development include EVO100, Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule, Rifalazil 25 milligram, Azithromycin 1 gram, solithromycin, ceftriaxone, azithromycin, PRO 2000/5, and others.
• On March 2023, IVIEW Therapeutics Inc announced a study of phase 2 clinical trials for IVIEW-1201. A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis.
• On May 2022, University of California, San Francisco announced a study of phase 4 clinical trials for Doxycycline Hyclate Delayed-Release 200 mg. The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact, can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration (FDA), taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use. Participants will take part in the study for 1 year.
Chlamydia Infections Overview
Chlamydial infection, caused by Chlamydia species, is the most common bacterial sexually transmitted infection and results in substantial morbidity and economic cost worldwide. Chlamydial infections can cause disease in many organ systems, including the genitourinary tract and ocular structures. Chlamydia is a sexually transmitted infectious disease caused by the bacterium Chlamydia trachomatis.
To explore more information on the latest breakthroughs in the Chlamydial infection Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Chlamydial infection Emerging Drugs Profile
• EVO100: Evofem Biosciences
• Chlamydia Infection Blockers (CIBs): Quretech Bio
Chlamydial infection Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Chlamydia Infections. The companies which have their Chlamydia Infections drug candidates in the most advanced stage, i.e. phase III include, Evofem Biosciences.
Request a sample and discover the recent advances in Chlamydial infection Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Chlamydial infection Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Chlamydial infection Therapeutics Market include-
Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.
Dive deep into rich insights for drugs for Chlamydial infection Pipeline, click here for Chlamydial infection Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Chlamydial infection Pipeline Report
• Coverage- Global
• Chlamydial infection Companies- Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others.
• Chlamydial infection Pipeline Therapies- EVO100, Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule, Rifalazil 25 milligram, Azithromycin 1 gram, solithromycin, ceftriaxone, azithromycin, PRO 2000/5, and others
• Chlamydial infection Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Chlamydial infection Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/chlamydia-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Chlamydia Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chlamydia Infections - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. EVO100: Evofem Biosciences
9. Drug profiles in the detailed report…..
10. Preclinical and Discovery Stage Products
11. Chlamydia Infection Blockers (CIBs): Quretech Bio
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Chlamydia Infections Key Companies
15. Chlamydia Infections Key Products
16. Chlamydia Infections- Unmet Needs
17. Chlamydia Infections- Market Drivers and Barriers
18. Chlamydia Infections- Future Perspectives and Conclusion
19. Chlamydia Infections Analyst Views
20. Chlamydia Infections Key Companies
21. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chlamydia Infections Pipeline, Clinical Trials Assessment, NDA Approvals, Emerging Drugs 2023 (Updated) | Evofem Biosciences, Aeterna Zentaris, LinKinVax, Sanofi, and others here
News-ID: 3138389 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Chlamydia
Chlamydia Diagnosis And Treatment Market Size Analysis by Application, Type, and …
According to Market Research Intellect, the global Chlamydia Diagnosis And Treatment market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for chlamydia diagnosis and treatment is expanding rapidly as a result of improvements in…
Preventive Healthcare Boosts Growth of Chlamydia Diagnostics Market Driver: Lead …
How Are the key drivers contributing to the expansion of the chlamydia infection diagnostics market?
The emphasis on preventive healthcare is anticipated to drive the growth of the chlamydia infection diagnostics market. Rather than treating diseases after their occurrence, preventive healthcare focuses on their prevention through consistent medical check-ups, immunizations, and changes in lifestyle. The goal is to lessen the cost of healthcare, enhance the quality of life, and keep chronic…
Key Trend Reshaping the Chlamydia Infection Diagnostics And Therapeutics Market …
What Are the Projections for the Size and Growth Rate of the Chlamydia Infection Diagnostics And Therapeutics Market?
In recent times, the market size for chlamydia infection diagnostics and therapeutics has seen a robust expansion. The projected growth is from $1.43 billion in 2024 to $1.51 billion in 2025, representing a CAGR of 5.9%. The historic growth has been influenced by factors such as a rise in sexual activity, enhancement in…
Chlamydia Diagnostic Market Analysis and Forecast 2024
"The Business Research Company recently released a comprehensive report on the Global Chlamydia Infection Diagnostics Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Chlamydia Pneumoniae Antibody Market: Rising Prevalence of Chlamydia Pneumoniae …
Global Chlamydia Pneumoniae Antibody Market Overview:
The Chlamydia Pneumoniae Antibody market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Chlamydia Pneumoniae Antibody market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth…
Chlamydia Infections-Pipeline Review H2 2018
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections-Pipeline Review, H2 2018,…
